Genmab | GEN - Sales Revenues


Genmab reported DKK1.06B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Almirall EUR 547.63M 12.83M Dec/2025
Amarin USD 49.22M 451K Dec/2025
Amgen USD 8.62B 1.28B Mar/2026
argenx SE USD 1.12B 0 Mar/2026
AstraZeneca USD 15.29B 213M Mar/2026
Bayer EUR 13.41B 1.97B Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Demant DKK 6.25B 800M Dec/2025
Exelixis USD 610.8M 12.14M Mar/2026
Fresenius Medical Care EUR 4.61B 460M Mar/2026
Genmab DKK 1.06B 36M Dec/2025
GlaxoSmithKline GBP 7.63B 991M Mar/2026
GN Store Nord DKK 3.85B 830M Mar/2026
GRIFOLS EUR 1.7B 280M Mar/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Insmed USD 305.96M 42.16M Mar/2026
Lakefront Biotherapeutics EUR 6.5M 894.32M Mar/2026
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.13B 120M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.24B 60M Mar/2026
UCB EUR 4.25B 764M Dec/2025